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Background
Natalizumab is an approved drug used in relapsing and
aggressive Multiple Sclerosis (MS). This is a monoclonal
anti-integrin antibody that decreases the transmigration of
immune cells through the blood-brain-barrier in animal
models of MS. In human, the number of T cells in the
CSF is dramatically decreased while the number of circu-
lating lymphocytes usually increases. We hypothesized
that in patients treated with natalizumab, the infiltration
of T cells in the brain parenchyma decreases. These cells
may accumulate in the blood of the patients and thus alter
the T cell repertoire.
Objectives
We assessed whether the treatment by natalizumab
resulted in the apparition of Vb clonal selections one year
after the beginning of the treatment.
Methods
The T Cell Receptor (TCR) repertoire was investigated by
the analysis of the CDR3 length distribution of the b
chain. The blood of MS patients was sampled just before
the beginning of Natalizumab, and six months and one
year after. CDR3 spectratyping was performed at those
three different time points. Each profile was assessed as
“gaussian”, “altered polyclonal”, “altered oligoclonal” or
“altered monoclonal” and the alterations observed were
compared.
Results
Four relapsing-remitting MS patients were included in
this study. At baseline, we observed more alterations in
the CD8+ compartment compared with the CD4+ one.
One year after the beginning of the treatment, the global
percentage of alterations did not increase for CD4+ or
CD8+ cells. However, for three patients, we observed the
apparition of private Vb clonal selections.
Discussion/perspectives
Given the mechanisms of action of natalizumab, one may
hypothesize that the clonal cells observed in the blood
after one year of treatment could have a major role in the
pathophysiological process in the disease. We now plan to
analyze the phenotype and the reactivity of these clones
against myelin antigens.
Author details
1INSERM U643, Nantes University, Nantes, France. 2Neurology Dept., Nantes
Hospital, Nantes, France.
Published: 23 November 2011
doi:10.1186/1479-5876-9-S2-P26
Cite this article as: Michel et al.: Natalizumab alters the TCR repertoire
after one year of treatment in four MS patients. Journal of Translational
Medicine 2011 9(Suppl 2):P26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1INSERM U643, Nantes University, Nantes, France
Full list of author information is available at the end of the article
Michel et al. Journal of Translational Medicine 2011, 9(Suppl 2):P26
http://www.translational-medicine.com/content/9/S2/P26
© 2011 Michel et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
